Eger K, Kroes JA, ten Brinke A, et al. - The present study was performed to evaluate prevalences and predictors of super-, partial- and non-responders to long-term anti-interleukin (IL)-5 treatment, frequency, and reasons for switches between anti-IL-5 biologics, nature of residual disease manifestations. A two-year follow-up study was performed to include severe asthma patients who initiated an anti-IL-5 biologic (mepolizumab, reslizumab, benralizumab) (n=114). The study found a favorable response in 83% of severe asthma patients, including a super-response in 14% after 2 years of anti-IL-5 treatment. As per the outcomes, most partial responders exhibit impaired lung function or uncontrolled sino-nasal disease, causing physicians to switch between biologics.